INAB Insider Trading
Insider Ownership Percentage: 15.50%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $0.00
IN8bio Share Price & Price History
Current Price: $0.26
Price Change: ▼ Price Decrease of -0.0283 (-9.90%)
As of 01/22/2025 05:00 PM ET
IN8bio Insider Trading History
IN8bio Institutional Trading History
Data available starting January 2016
IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidates include INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation; and INB-400, which is in Phase 2 clinical trial to treat newly diagnosed GBM. It also develops INB-300, INB-410, and INB-500 that are in preclinical Phase for treatment of various solid tumor cancers. The company was formerly known as Incysus Therapeutics, Inc. and changed its name to IN8bio, Inc. in August 2020. IN8bio, Inc. was incorporated in 2016 and is headquartered in New York, New York.
Read More on IN8bio
Volume
730,897 shs
Average Volume
962,011 shs
Market Capitalization
$18.68 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.04
Who are the company insiders with the largest holdings of IN8bio?